FAST NEWS: Everest Medicines Plunges After Terminating Breast Cancer Drug Deal
The latest: Everest Medicines Ltd. (1952.HK) announced Tuesday that it is terminating its agreement to develop Gilead Science’s (GILD.US) Sacituzumab Govitecan breast cancer drug for the China market. Looking up:…
RELATED ARTICLES
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Cancer drug maker Biostar shines on Hong Kong market debut
2563.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
BRIEF: Everest unveils positive results for kidney drug EVER001 in Phase 1b/2a trial
1952.HK
Discover hidden China stock gems in our weekly newsletter